The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22%.

The proposed acquisition gives Wise Equity control of a specialist oral solid-dose manufacturer with established capabilities in effervescent, soluble, orally disintegrating and sublingual formulations.

The deal gives Bayer additional financial flexibility while allowing the company to retain operational control of its long-acting reversible contraceptives portfolio.

Germany’s healthcare system overhaul introduces billions in savings measures while increasing pressure on pharmaceutical companies.

The combination forms one of the largest dedicated healthcare investors globally, spanning pharma, medtech, diagnostics, and healthcare infrastructure across three continents.